{"id":9617,"date":"2020-02-11T13:32:35","date_gmt":"2020-02-11T13:32:35","guid":{"rendered":"https:\/\/laforcedmd.com\/?p=9617"},"modified":"2022-05-03T18:05:40","modified_gmt":"2022-05-03T18:05:40","slug":"viltolarsen-under-priority-review-by-the-fda-exon-skipping-53","status":"publish","type":"post","link":"https:\/\/laforcedmd.com\/en\/viltolarsen-under-priority-review-by-the-fda-exon-skipping-53\/","title":{"rendered":"Viltolarsen under priority review by the FDA"},"content":{"rendered":"

The U.S. Food & Drug Administration (FDA) had accepted the filing of a New Drug Application (NDA) under the priority review for viltolarsen in patients with Duchenne Muscular Dystrophy (DMD) who are amenable to exon 53 skipping therapy.<\/strong><\/h4>\n

Read the full News Release<\/a><\/span><\/p>\n

KYOTO, Japan and PARAMUS, NJ: February 7, 2020 – <\/em><\/span><\/p>\n

Nippon Shinyaku Co., Ltd.<\/a><\/span> and NS Pharma, Inc. <\/a><\/span>announced that the U.S. Food & Drug Administration (FDA) had accepted the filing of a New Drug Application (NDA) under the priority review for viltolarsen in patients with Duchenne Muscular Dystrophy (DMD) who are amenable to exon 53 skipping therapy.<\/strong> In addition to priority review, the FDA previously granted viltolarsen with Fast Track, Orphan Drug and Rare Disease designations. The viltolarsen NDA includes results from a Phase 2 study and its long-term extension study in North America — as well as a Phase 1 and a Phase 1\/2 study in Japan. Both the Phase 1\/2 and Phase 2 studies evaluated changes in dystrophin levels and motor function across two doses. The PDUFA (Prescription Drug User Fee Amendments<\/a><\/span>) date for viltolarsen is within the 3 rd quarter (July-September) of 2020. The PDUFA date is the target date the FDA provides a decision on the approval of a new drug. Viltolarsen represents one of the most extensively studied antisense therapies in DMD. Viltolarsen, if approved by the FDA, would represent a new treatment option for DMD patients amenable to exon 53 skipping in the United States.<\/strong><\/p>\n

About Viltolarsen<\/h4>\n

Viltolarsen has been granted a Rare Pediatric Disease Designation<\/a><\/span>, Orphan Drug Designation<\/a><\/span>, and a Fast Track Designation<\/a><\/span> in the U.S., and “SAKIGAKE designation,” “Orphan drug designation,” and designation of Conditional Early Approval System in Japan. Viltolarsen is not approved by any regulatory authority and its safety and effectiveness have not been established.<\/p>\n

Mechanism of Action<\/h4>\n

Exon skipping is a potential therapy that is being developed for patients with DMD<\/strong>. Specialized molecules are created to skip over the non-working part of the dystrophin gene and allow pieces of the puzzle to attach. It creates a smaller puzzle, but a puzzle that may produce some of the protein that muscles need to work correctly. NS-065\/NCNP-01-201 Phase II dose-finding study<\/a><\/span> is evaluating the safety and dosing of an investigational medication called NS-065\/NCNP-01 (Viltolarsen), in the treatment of boys with DMD who have specific changes in the dystrophin gene that may be helped with the skipping of exon 53.<\/strong><\/p>\n

More links<\/h4>\n